

AXE 4 :

Equipes participantes et publications associées

Site de Bruxelles

Unité de recherche en Psychosomatique et en Psycho-oncologie

Directeur : Pr Darius Razavi

Faculté des sciences psychologiques et de l'éducation

Campus du Solbosch

Université Libre de Bruxelles

Avenue F.D. Roosevelt

B-1050 Bruxelles

Belgique

Tél. : +32-2-650.36.16

Fax : +32-2-650.22.09

Contact : Pr Darius Razavi, Dr Nicole Delvaux

Email : drazavi@ulb.ac.be, ndelvaux@ulb.ac.be

Publications

1. LIBERT Y., JANNE P., **RAZAVI D.**, MERCKAERT I., SCALLIET P., **DELVAUX N.**, ETIENNE A-M., CONRADT S., KLASTERSKY J., BONIVER J., REYNAERT Ch. British Journal of Cancer 88, 502-509, 2003. «Patients' satisfaction ratings and their desire for care improvement across oncology settings from France, Italy, Poland and Sweden».
2. BRÉDART A., ROBERTSON C., **RAZAVI D.**, BATEL-COPEL L., LARSSON G., LICHOSIK D., MEYZA J., SCHRAUB S., VON ESSEN L. AND DE HAES J.C.J.M. Psycho-Oncology 12, 68-77, 2003.«How to optimise physicians' communication skills in cancer care: Results of a randomised study assessing the usefulness of post training consolidation workshops».
3. **RAZAVI D.**, MERCKAERT I, MARCHAL S, LIBERT Y, CONRADT S, BONIVER J, ETIENNE A, FONTAINE O, JANNE P, KLASTERSKY J, REYNAERT C, SCALLIET P, SLACHMUYLDER J-L, DELVAUX N. Journal of Clinical Oncology 21(16), 3141-3149, 2003.«La communication non verbale des médecins face à un patient atteint du cancer».
4. MAYER C, MERCKAERT I, **RAZAVI D.** Revue Francophone de Psycho-Oncologie 3, 57-63, 2003. «Effects of a 105 hours psychological training program on attitudes, communication skills and occupational stress in oncology : a randomised study».

5. **DELVAUX N, RAZAVI D, MARCHAL S, BREDART A, FARVACQUES C** and **SLACHMUYLDER J-L**. British Journal of Cancer 90, 106-114, 2004. «Physicians are different when they learn communication skills : Influence of the Locus of Control»
6. **LIBERT Y, MERCKAERT I, REYANAERT C, DELVAUX N, MARCHAL S, ETIENNE A-M, BONIVER J, KLASTERSKY J, SCALLIET P, SLACHMUYLDER J-L, RAZAVI D**. Psycho-Oncology 13(8), S71, 2004. «Research in the behavioural and social sciences to improve cancer control and care : a strategy for development»
7. **RAZAVI D** .Revue de la Société Suisse de Médecine et de Soins Palliatifs 3, 14-16,2005. «Physicians' communication with a cancer patient and a relative: a randomised study assessing the efficacy of consolidation workshops».
8. **DELVAUX N, MERCKAERT I, MARCHAL S, LIBERT Y, CONRADT S, BONIVER J, ETIENNE A, FONTAINE O, JANNE P, KLASTERSKY J, MELOT C, REYNAERT C, SCALLIET P, SLACHMUYLDER J-L, RAZAVI D**. Cancer 103(11): 2397-411, 2005. «Communication skills training in cancer care: where are we and where are we going?»
9. **MERCKAERT I, LIBERT Y, RAZAVI D**. Current Opinion in Oncology 17(4): 319-30, 2005. «Factors that influence physicians' detection of distress in patients with cancer : Can a communication skills training program improve physicians' detection?»
10. **MERCKAERT I, LIBERT Y, DELVAUX N, MARCHAL S, BONIVER J, ETIENNE A-M, KLASTERSKY J, REYNAERT C, SCALLIET P, SLACHMUYLDER J-L, RAZAVI D**. Cancer 104(2), 411-421, 2005.«An International Prospective Study of the EORTC Cancer In-Patient Satisfaction with Care Meaure (EORTC IN-PATSAT32)»
11. **BRÉDART A, BOTTOMLEY A, BLAZEYBY J, CONROY T, COENS C, D'HAESE S, CHIE W-C, HAMMERLID E, ARRARAS JI, EFFICACE F, RODARY C, SCHRAUB S, COSTANTINI M, COSTANTINI A, JOLY F, SEZER O, RAZAVI D, MEHLITZ M, BIELSKA-LASOTA M, AARONSON NK** on behalf of the European Organisation for Research and Treatment of Cancer Quality of Life Group and Quality of Life Unit. European Journal of Cancer 41: 2120-2131, 2005.
12. **MERCKAERT I, LIBERT Y, RAZAVI D**. Psycho-oncology 14(10), 829-830, 2005. «Being known : patients' perspectives of the dynamics of human connection in cancer care ».
13. **MERCKAERT I, LIBERT Y, RAZAVI D**. Psycho-oncology 14, 899-900, 2005. «Breast cancer : communication with a breast cancer patient and a relative. »
14. **MERCKAERT I, LIBERT Y, RAZAVI D**. Annals of Oncology 16(suppl 2), ii209-ii212, 2005.«Teaching communication and stress management skills to junior physicians dealing with cancer patients :a Belgian Interuniversity Curriculum».

15. BRAGARD I, **RAZAVI D**, MARCHAL S, MERCKAERT I, **DELVAUX N**, LIBERT Y, REYNAERT C, BONIVER J, KLASTERSKY J, SCALLIET P, ETIENNE A-M Supportive Care in Cancer, 14, 454-461, 2005.«Formation des psychologues et des psychiatres à la psycho-oncologie».
16. BACQUE M.-F., **RAZAVI D**. Oncologie 7, 173-178, 2005.« Adjustment disorders in oncology: a conceptual framework to be refined ».
17. **RAZAVI D**. Bulletin et Mémoires de l'Académie royale de Médecine de Belgique 161(1-2), 127-137, 2006. «Does a psychological characteristic influence physicians communication style ? Impact of physicians' locus of control on interviews with a cancer patient and a relative».
18. LIBERT Y, MERCKAERT I ; REYNAERT C, **DELVAUX N**, MARCHAL S, ETIENNE A-M , BONIVER J, KLASTERSKY J, SCALLIET P, SLACHMUYLDER J-L, **RAZAVI D**. Supportive Care in Cancer 14(3), 230-242, 2006a.« Les enjeux, objectifs et particularités de la communication médecin-malade en oncologie : état des lieux et perspectives futures ».
19. LIBERT Y., MERCKAERT I., REYNAERT C., **RAZAVI D**. Bulletin du Cancer 93(4), 357-62, 2006,« Quelle est la place du sevrage tabagique chez les patients atteints d'une affection cancéreuse ? ».
20. LIBERT Y ; MERCKAERT I; ETIENNE A-M; FARVACQUES C, LIENARD A, MESSIN S, MEUNIER J, MILANI M, MOUCHEUX A, REYNAERT C, SALIS J, SLACHMUYLDER J-L , **RAZAVI D**. Oncologie 8, 465-476, 2006. «Factors that influence cancer patients' anxiety following a medical consultation : impact of a communication skills training programme for physicians. »

Site de Caen

Unité de Recherche Clinique

Directeur : Michel Henry-Amar

Centre François Baclesse

3 avenue du Général Harris

14076 CAEN CEDEX 05

Tel : 02.31.45.50.02

Fax : 02.31.45.50.97

Contact : Pr. Florence Joly et Dr Michel Henry-Amar

Email : f.joly@baclesse.fr, m.henry.amar@baclesse.fr

Principales publications

1. Berthe E, **Henry-Amar M**, Michels JJ, Rame JP, Berthet P, Babin E, Icard P, Samama G, Galateau-Salle F, Mahoudeau J, Bardet S. Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2004;31(5):685-91.

2. Andre M, Mounier N, Leleu X, Sonet A, Brice P, **Henry-Amar M**, Tilly H, Coiffier B, Bosly A, Morel P, Haioun C, Gaulard P, Reyes F, Gisselbrecht C; Groupe D'Etude Des Lymphomes De L'Adulte. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. *Blood* 2004;103(4):1222-8.
3. Andre M, Mounier N, Leleu X, Sonet A, Brice P, **Henry-Amar M**, Tilly H, Coiffier B, Bosly A, Morel P, Haioun C, Gaulard P, Reyes F, Gisselbrecht C. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. *Blood* 2004;103(4):1222-8.
4. Babin E, **Joly F**, Vadillo M, Dehesdin D. Qualité de vie en cancérologie. Application aux cancers des voies aérodigestives supérieures. *Ann Otolaryngol Chir Cervicofac* 2005;122(3):134-41.
5. Bredart A, Bottomley A, Blazeby JM, Conroy T, Coens C, D'Haese S, Chie WC, Hammerlid E, Arraras JI, Efficace F, Rodary C, Schraub S, Costantini M, Costantini A, **Joly F**, Sezer O, Razavi D, Mehlitz M, Bielska-Lasota M, Aaronson NK; European Organisation for Research and Treatment of Cancer Quality of Life Group and Quality of Life Unit. An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32). *Eur J Cancer* 2005;41(14):2120-31.
6. **Joly F**, Alibhai SM, Galica J, Park A, Yi QL, Wagner L, Tannock IF. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. *J Urol* 2006;176(6 Pt 1):2443-7.
7. **F.Joly**. L'âge est-il toujours un facteur limitant dans la prise en charge des patients atteints de cancers ?
Rev Fr Psycho-oncol 2006, Editorial 1 : 1-2
8. Bourgeois H, **Joly F**, Pujade-Lauraine E, Cure H, Guastalla JP, Ferru A, Chabrun V, Chieze S, Tourani JM. Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients. *Am J Clin Oncol* 2006;29(4):399-404.
9. Bourgeois H, Ferru A, Lortholary A, Delozier T, Boisdron-Celle M, Abadie-Lacourtoisie S, **Joly F**, Chieze S, Chabrun V, Gamelin E, Tourani JM. Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer. *Am J Clin Oncol* 2006;29(3):267-75.
10. **Joly F**, Bourgeois H, Floquet A, Chinet-Charrot P, Meyer F, Lebrun D, Hamond K, Leroy C, Heron JF. Efficacy and tolerability of the ifosfamide-epirubicin combination in relapsed ovarian cancer. *Int J Gynecol Cancer* 2006;16(1):77-82.
11. Franklin J, Pluetschow A, Paus M, Specht L, Anselmo AP, Aviles A, Biti G, Bogatyreva T, Bonadonna G, Brilliant C, Cavalieri E, Diehl V, Eghbali H, Ferme C, **Henry-Amar M**, Hoppe R, Howard S, Meyer R, Niedzwiecki D, Pavlovsky S, Radford J, Raemaekers J, Ryder D, Schiller P, Shakhtarina S, Valagussa P, Wilimas J, Yahalom J. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. *Ann Oncol*. 2006;17(12):1749-60.

12. **Joly F**, Bourgeois H, Floquet A, Chinet-Charrot P, Meyer F, Lebrun D, Hamond K, Leroy C, Heron JF. Efficacy and tolerability of the ifosfamide-epirubicin combination in relapsed ovarian cancer. *Int J Gynecol Cancer* 2006;16(1):77-82.
13. Aleman BM, Raemaekers JM, Tomšič R, Baaijens MH, Bortolus R, Lybeert ML, van der Maazen RW, Girinsky T, Demeestere G, Lugtenburg P, Lievens Y, de Jong D, Pinna A, **Henry-Amar M** on behalf of the European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's Lymphoma. *Int J Radiat Oncol Biol Phys* 2007;67(1):19-30.
14. Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van Den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JMM, Salles G, Gerrits WBJ, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, **Henry-Amar M** for the European Organization for Research and Treatment of Cancer Lymphoma Group and the Groupe d'Études des Lymphomes de l'Adulte. Combined modality treatment for early stages Hodgkin's lymphoma based on prognostic factors. Results of the EORTC–GELA H8 trial. *N Engl J Med* (Accepté).
15. Michels JJ, Jacques M, **Henry-Amar M**, Bardet S. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. *Hum Pathol* 2007;38(2):212-219.
16. Michels JJ, Marnay J, **Henry-Amar M**, Bardet S. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. *Human Pathol* 2007 (Sous presse).
17. Bredart A, Coens C, Aaronson N, Chie WC, Efficace F, Conroy T, Blazeby JM, Hammerlid E, Costantini M, **Joly F**, Schraub S, Sezer O, Arraras JI, Rodary C, Costantini A, Mehlitz M, Razavi D, Bottomley A; on behalf of the EORTC Quality of Life Group and the EORTC Quality of Life Unit. Determinants of patient satisfaction in oncology settings from European and Asian countries: preliminary results based on the EORTC IN-PATSAT32 questionnaire. *Eur J Cancer* 2007;43(2):323-30.
18. **F Joly**, J Vardy, M Pintilie, I Tannock. Critical Review of the Analysis of Quality of Life and/or Symptom Control in Randomized Clinical Trials for Patients with Advanced Cancer: How to Do It and What to Avoid. *Annals of Oncology*, sous presse
29. van der Kaaij MAE, Heutte N, Le Stang N, Raemaekers JMM, Simons AHM, Carde P, Noordijk EM, Fermé C, Thomas J, Eghbali H, Kluin-Nelemans HC, **Henry-Amar M**. Gonadal function in males after chemotherapy for early stage Hodgkin's lymphoma treated in four subsequent EORTC trials. *J Clin Oncol* (Sous presse).
20. Eymard JC, Priou F, Zannetti A, Ravaud A, Lepille D, Kerbrat P, Gomez P, Paule B, Genet D, Herait P, Ecstein-Fraisse E, **Joly F**. Randomized phase II study of docetaxel plus estramustine and

single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 2007 (Sous presse).

Unité Inserm-EPHE-UCBN EO218

Directeur : Pr. Francis Eustache

Laboratoire de Neuropsychologie

CHU

Avenue de la Côte de Nacre

14033 CAEN Cedex

Tél. : 02 31 06 51 97

Fax : 02 31 06 51 98

Contact : Pr. Francis Eustache, Dr Bénédicte Giffard

Email : neuropsych@chu-caen.fr, eustache@cyceron.fr, benedicte.giffard@unicaen.fr

Publications

1. Bernard F, Desgranges B, **Eustache F**, Baron JC (2007) Neural correlates of age-related verbal episodic memory decline: A PET study with combined subtraction/correlation analysis. Neurobiol.Aging .(sous presse)(IF, 5.312)
2. Chételat G, Landeau B, **Eustache F**, Mézenge F, Viader F, de la Sayette V, Desgranges B, Baron JC (2005) Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage 27: 934-946. (IF, 5.288)
3. Desgranges B, Matuszewski V, Piolino P, Chételat G, Mézenge F, Landeau B, de la Sayette V, Belliard S, **Eustache F** (2007) Anatomical and functional alterations in Semantic Dementia: a voxel based MRI and PET study. Neurobiol.Aging. (sous presse) (IF, 5.312)
4. **Eustache F**, Piolino P, **Giffard B**, Viader F, de la Sayette V, Baron JC, Desgranges B (2004) "In the course of time": a PET study of the cerebral substrates of autobiographical amnesia in Alzheimer's disease. Brain 127: 1549-1560. (IF, 7.535)
5. **Giffard B**, Desgranges B, Nore-Mary F, Lalevée C, Beaunieux H, de la Sayette V, Pasquier F, **Eustache F** (2002) The dynamic time course of semantic memory impairment in Alzheimer's disease: clues from hyperpriming and hypoprimering effects. Brain 125: 2044-2057. (IF, 7.535)
6. Hubert V, Beaunieux H, Chételat G, Platel H, Landeau B, Danion JM, Viader F, Desgranges B, **Eustache F** (2007) The dynamic network subserving the three phases of cognitive procedural learning. Human Brain Mapping. (sous presse) (IF, 4.317)
7. Lambert J, Giffard B, Nore F, de la Sayette V, Pasquier F, **Eustache F** (2007) Agraphia in AD: from the case of Auguste D. to a cognitive neuropsychology analysis. Cortex (sous presse) (IF, 3.584)

8. Lecardeur L, **Giffard B**, Laisney M, Brazo P, Delamillieure P, **Eustache F**, Dollfus S (2007) Semantic hyperpriming in schizophrenic patients: facilitation or defect of inhibition in semantic association processing? *Schizophr Res* 89 : 243-250. (IF, 4.231)
9. Martins S, **Guillery-Girard B**, Jambaqué I, Dulac O, **Eustache F** (2006) How children suffering severe amnesic syndrome acquire new concepts? *Neuropsychologia*. 44:2792-2805 (IF, 4.119)
10. Matuszewski V, Piolino P, de la Sayette V, Lalevée C, Pélerin A, Dupuy B, Viader F, **Eustache F**, Desgranges B (2006) Retrieval mechanisms for autobiographical memories: insights from the frontal variant of frontotemporal dementia. *Neuropsychologia* 44: 2386-2397 (IF, 4.119)
11. Mevel K, Desgranges B, Baron J-C, Landeau B, de la Sayette V, Viader F, **Eustache F**, Chételat G (2007). Detecting hippocampal hypometabolism in Mild Cognitive Impairment using automatic voxel-based approaches. *NeuroImage*. (sous presse) (IF, 5.288)
12. Orban P, Rauchs G, Balteau E, Degueldre C, Luxen A, Maquet P, Peigneux P, **Eustache F** (2006) Sleep after spatial learning promotes covert reorganization of brain activity. *Proc Natl Acad Sci USA* 103:7124-7129 (IF, 10.231)
13. Piolino P, Desgranges B, Belliard S, Matuszewski V, Lalevée C, de la Sayette V, **Eustache F** (2003) Autobiographical memory and auto-noetic consciousness: triple dissociation in neurodegenerative diseases. *Brain* 126: 2203-2219. (IF, 7.535)
14. Piolino P, Desgranges B, Manning L, North P, Jokic C, **Eustache F** (2007). Autobiographical memory, the sense of recollection and executive functions after severe traumatic brain injury. *Cortex* 43 : 176-195 (IF, 3.584)
15. Platel H, Baron JC, Desgranges B, Bernard F, **Eustache F** (2003) Semantic and episodic memory of music re subserved by distinct neural networks. *Neuroimage* 20: 244-256. (IF, 5.288)
16. Quinette P, **Guillery-Girard B**, Dayan J, de la Sayette V, Marquis S, Viader F, Desgranges B, **Eustache F** (2006) What does Transient Global Amnesia really mean? Review of the literature and thorough study of 142 cases. *Brain* 129: 1640-1658 (IF, 7.535)
17. Quinette P, **Guillery-Girard B**, Noël A, de la Sayette V, Viader F, Desgranges B, **Eustache F** (2006) The relationship between working memory and episodic memory disorders in Transient Global Amnesia. *Neuropsychologia* 44: 2508-2519 (IF, 4.119)
18. Rauchs G, Lebreton K, Bertran F, Pélerin A, Clochon P, Denise P, Foret J, Desgranges B, **Eustache F** (2006) Effects of partial sleep deprivation on within-format and cross-format priming. *Sleep* 26: 58-68 (IF, 4.950)
19. Rauchs G, Piolino P, Mézenge F, Landeau B, Lalevée C, Pélerin A, Viader F, de la Sayette V, **Eustache F**, Desgranges B (2007) Auto-noetic consciousness in Alzheimer's disease: neuropsychological and PET findings using an episodic learning and recognition task. *Neurobiol.Aging*. (sous presse) (IF, 5.312)

20. Viard A, Piolino P, Desgranges B, Chételat G, Lebreton K, Landeau B, Young A, de la Sayette V, **Eustache F** (2007). Hippocampal activation for autobiographical memories over the entire lifetime in healthy aged subjects: an fMRI study. *Cerebral Cortex* (sous presse) (IF, 6.187)

UMR-CNRS 6185

Directeur : Bernard Mazoyer

Equipe CERVOXY, «Hypoxie et physiopathologie cérébrovasculaire»

Responsable d'équipe : Myriam Bernaudin et Edwige Petit

Centre CYCERON,

Bd Henri Becquerel, BP5229,

14074 CAEN CEDEX

Tél : 02 31 47 01 03

Fax: 02 31 47 02 22

Contact : Dr Myriam Bernaudin, Dr Jean-Sébastien Guillamo, Dr Samuel Valable

Email : bernaudin@cyceron.fr, guillamo@cyceron.fr, valable@cyceron.fr

Publications

1. **DE BOUARD S, GUILLAMO JS, CHRISTOV C, LEFÈVRE N, BRUGIÈRE P, INDRACCOLO S, PESCHANSKI M (2003) Anti-angiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin or endostatin. Hum Gene Ther 14: 883-95. [IF 4.857]**
2. **GUILLAMO JS, CRÉANGE A, KALIFA C, GRILL J, RODRIGUEZ D, DOZ F, BARBAROT S, ZERAH M, SANSON M, BASTUJI-GARIN S, WOLKEINSTEIN P (2003) Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 126: 152-160. [IF 8.201]**
3. **VALABLE S, BELLAIL A, LESNÉ S, LIOT G, MacKENZIE ET, VIVIEN D, BERNAUDIN M, PETIT E (2003) Angiopoietin-1-induced PI3-kinase activation prevents neuronal apoptosis. FASEB J 17:443-445. [IF 6.82]**
4. **BENCHENANE K, LOPEZ-ATALAYA JP, FERNANDEZ-MONREAL M, TOUZANI O, VIVIEN D. (2004). Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci. 27: 155-160. [IF 14.80]**
5. **LAURENT N, DE BOUARD S, GUILLAMO JS, CHRISTOV C, ZINI R, JOUAULT H, ANDRÉ P, LOTTEAU V, PESCHANSKI M (2004) Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. Mol Cancer Ther 3: 129-136. [IF 5.242]**
6. **SHARP FR AND BERNAUDIN M. (2004). HIF1 and oxygen sensing in brain. Nat. Rev. Neurosci. 5: 437-448. [IF 21.22]**

7. VERA K, DJAFARI L, FAIVRE S, **GUILLAMO JS**, DJAZOULI K, OSORIO M, PARKER F, CIOLOCA C, ABDULKARIM B, ARMAND JP, RAYMOND E. (2004) Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. *Ann Oncol* 15:161-71. [IF 4.335]
8. BENCHENANE K, BEREZOWSKI V, ALI C, FERNANDEZ-MONREAL M, LOPEZ-ATALAYA JP, BRILLAULT J, CHUQUET J, NOUVELOT A, MacKENZIE ET, BU G, CECHELLI R, TOUZANI O, VIVIEN D. (2005). Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. *Circulation*. 111: 2241-2249. [IF 12.56]
9. BENCHENANE K, BEREZOWSKI V, FERNANDEZ-MONREAL M, BRILLAULT J, **VALABLE S**, DEHOUCK, MP, CECHELLI R, VIVIEN D, TOUZANI O, ALI C. (2005). Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process. *Stroke*. 36:1065-1070. [IF 5.74]
10. DAGNON K, PACARY E, COMMO F, ANTOINE M, **BERNAUDIN M**, BERNAUDIN JF, CALLARD P. (2005). Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. *Clin Cancer Res*. 11: 993-999. [IF 5.62]
11. **VALABLE S**, MONTANER J, BELLAIL A, BEREZOWSKI V, BRILLAULT J, CECHELLI R, DIVOUX D, MacKENZIE ET, **BERNAUDIN M**, ROUSSEL S, PETIT E. (2005). VEGF-induced BBB permeability is associated with an MMP-9 activity increase in cerebral ischemia: both effects decreased by Ang-1. *J Cereb Blood Flow Metab*. 25: 1491-1504. [IF 5.67]
12. TANG Y, PACARY E, FRERET T, DIVOUX D, PETIT E, SCHUMANN-BARD P, **BERNAUDIN M**. (2006). Effect of hypoxic preconditioning on brain genomic response before and following ischemia in the adult mouse: Identification of potential neuroprotective candidates for stroke. *Neurobiol Dis*. 21(1):18-28. [IF 4.38]
13. ALTHAUS J, **BERNAUDIN M**, PETIT E, TOUTAIN J, TOUZANI O, RAMI A. (2006). Expression of the gene encoding the pro-apoptotic BNIP3 protein and stimulation of hypoxia-inducible factor-1alpha (HIF-1alpha) protein following focal cerebral ischemia in rats. *Neurochem. Int*. 48(8):687-95. [IF 3.21]
14. FRERET T, **VALABLE S**, CHAZALVIEL L, SAULNIER R, MacKENZIE ET, PETIT E, **BERNAUDIN M**, BOULOUARD M, SCHUMANN-BARD P. (2006). Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat. *Eur J Neurosci*. 23(7):1757-65. [IF 3.82]
15. LECHAPT-ZALCMAN E, PRULIERE-ESCABASSE V, ADVENIER D, GALIACY S, CHARRIERE-BERTRAND C, COSTE A, HARF A, D'ORTHO MP, ESCUDIER E. (2006). Transforming Growth Factor- β 1 increases airway wound repair via MMP-2 up-regulation: a

new pathway for epithelial wound repair? Am J Physiol Lung Cell Mol Physiol, 2006; 290(6):L1277-82. Epub 2006 Jan 13. [IF 4.22]

16. PACARY E, LEGROS H, **VALABLE S**, DUCHATELLE P, LECOCQ M, PETIT E, NICOLE O, **BERNAUDIN M**. (2006). Synergistic effects of CoCl₂ and ROCK inhibition on mesenchymal stem cell differentiation into neuron-like cells. J Cell Sci. 119(Pt 13):2667-78. [IF 6.91]
17. PACARY E, TIXIER E, COULET F, ROUSSEL S, PETIT E, **BERNAUDIN M**. (sous presse). Crosstalk between HIF-1 and ROCK pathways in neuronal differentiation of mesenchymal stem cells, neurospheres and in PC12 neurite outgrowth. Mol Cell Neurosci. [IF 4.64]
18. KEIME-GUIBERT F, CHINOT O, TAILLANDIER L, CARTALAT-CAREL S, FRENAY M, KANTOR G, **GUILLAMO JS**, JADAUD E, COLIN P, BONDIAU PY, MENEI P, LOISEAU H, BERNIER V, HONNORAT J, BARRIE M, MOKHTARI K, MAZERON JJ, BISSERY A, DELATTRE JY; Association of French-Speaking Neuro-Oncologists. (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med. 356(15):1527-35. [IF 44.01]
19. DE BOÛARD S, HERLIN P, CHRISTENSEN JG, LEMOISSON E, GAUDUCHON P, RAYMOND E, **GUILLAMO JS**. Anti-angiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro-Oncol, sous presse [IF 4.15]
20. DOU W, RUAN S, BLOYET D, CONSTANS JM. Fuzzy Information Fusion Scheme Used to Segment Brain Tumor from MR Images. Image and Vision Computing, sous presse. [IF 1.38]

UMR-CEA 2E GDM-TEP « Groupe de Développements Méthodologiques en Tomographie par Emission de Positons »

Directeur : Louisa barré

Centre CYCERON,

Bd Henri Becquerel, BP 5229

14074 CAEN Cedex

Tél : 02 31 47 02 24

Fax : 02 31 47 02 22

Contact : Dr Louisa Barré

Email : barre@cyceron.fr

Publications

1. DEBRUYNE D, SOBRIO S, HINSCHBERGER A, CAMSONNE R, COQUEREL A, **BARRÉ L**. (2003). Short term pharmacokinetics of brain distribution of mecamlamine as a

- preliminary to ¹¹C labelling for nicotinic receptor investigation. *J. Pharm. Sci.* 92: 1051-1057. [IF 2.270]
2. BAGOT-GUERET C, LE BAS M-D, TYMCIU S, DARABANTU M, EDMOND P, GUILLOTEAU D, LASNE M-C, WILJKHUISEN Z, **BARRÉ L**, PERRIO C. (2003). Synthesis and biological evaluation of halogenated naphthyridone carboxamides as potential ligands for in vivo imaging studies of substance P receptors. *Bioconjugate Chem.* 14: 629-641. [IF 3.044]
 3. CHESNAY E, BABIN E, CONSTANS J-M, AGOSTINI D, BEQUIGNON A, REGEASSE A, SOBRIO F, MOREAU S. (2003). Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome. (2003) *J. Nucl. Med.* 44: 526-532. [IF 4.51]
 4. LEMOUCHEUX L, ROUDEN J, IBAZIZENE M, SOBRIO F, and LASNE M-C. (2003) Debenzylation of tertiary amines using phosgene or triphosgene: an efficient and rapid procedure for the preparation of carbamoyl chlorides and unsymmetrical ureas. Application in carbon-11 chemistry. *J. Org. Chem.* 68: 7289-7297. [IF 3.28]
 5. AIDE N, CAPELLE O, BOTTET Ph, BENSADOUN H, REGEASSE A, COMOZ F, SOBRIO F, BOUVARD G, AGOSTINI D. (2003). [¹⁸F]-FDG PET efficiency to characterise renal cancer and detect distant metastases. A comparison with CT. *Eur. J. Nucl. Med. Mol. Imaging.* 30: 1236-1245.
 6. BENNACEF I, TYMCIU S, DHILLY M, MONGIN F, QUEQUINER G, LASNE M-C, **BARRÉ L**, PERRIO C. (2004). Lithiation of functionalised fluoroquinolines: synthesis of dihalo-2-phenylquinoline-4-carboxamides and in vitro evaluation as NI-3 receptor ligands for Medical Imaging Studies. *J. Org. Chem.* 69: 2622-22625. [IF 3.28]
 7. BENNACEF I, TYMCIU S, DHILLY M, LASNE M-C, DEBRUYNE D, PERRIO C, **BARRÉ L**. (2004). Synthesis and biological evaluation of fluoro and iodo-quinoline carboxamides as potential ligands of NK-3 receptors for in vivo imaging studies. *Bioorg. Med. Chem.* 12: 4533-4541. [IF 1.798]
 8. SOBRIO F, DEBRUYNE D, DHILLY M, CHAZALVIEL L, CAMSONNE R, KAKIUCHI T, TSUKADA H, **BARRÉ L**. (2005). Evaluation in rats and primates [¹¹C]-mecamylamine, a potential nicotinic acetylcholine receptor radioligand for positron emission tomography. *Neurochem. Int.* 46: 479-488. [IF 3.04]
 9. QUENTIN T, DEBRUYNE D, LELONG-BOULOUARD V, POISNEL G, **BARRÉ L**, COQUEREL A. (2005). Clorazepate affects cell surface regulation δ and κ opioid receptors, there by altering buprenorphine-induced adaptation in the rat brain. *Brain Res.* 1063: 84-95. [IF 2.489]
 10. DEBRUYNE D, QUENTIN T, POISNEL G, LELONG-BOULOUARD V, **BARRÉ L**, COQUEREL A. (2005). Acute and chronic administration of clorazepate modifies the cell

- surface regulation of mu opioid induced by buprenorphine in specific regions of the rat brain. *Brain Res.* 1052: 222-231. [IF 2.489]
11. HALLEY A, HUGENTOBLER A, ICARD P, PORRET E, SOBRIO F, LEROCHAIS J-P, BOUVARD G, ZALCMAN G, AGOSTINI D. (2005). Efficiency of ^{18}F -FDG and $^{99\text{mTc}}$ -depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules. *Eur. J. Nucl. Med. Mol. Imaging.* 32: 1026-1032.
 12. GRANDEURY A, PETIT S, COSTE S, COQUEREL G, PERRIO C, GOUHIER G. (2005). New synthesis of (*Z,E*)-2,7-bis(4-cyanobenzylidene)cycloheptan-1-one under stereospecific constraints induced by host-guest interactions. *Chem. Commun.* 4007-4009. [IF 3.902]
 13. DUVELLEROY D, PERRIO C, PARISEL O, LASNE M-C. (2005). Rapid synthesis of quinoline-4-carboxylic acid derivatives from arylimines and 2-substituted acrylates or acrylamides under indium(III) chloride and microwave activations. Scope and limitations of the reaction. *Org. Biomol. Chem.* 3: 3794-3804.
 14. LELONG-BOULOUARD V, QUENTIN T, MOREAUX F, DEBRUYNE D, BOULOUARD M, COQUEREL A. (2006). Interactions of buprenorphine and dipotassium clorazepate on anxiety and memory functions in the mouse. *Drug Alcohol Depen.* 85: 103-113. [IF 2.211]
 15. POISNEL G, QUENTIN T, **BARRÉ L**, DEBRUYNE D. (2006). Competitive displacement binding assay on rat brain sections and using a beta-imager : Application to mu-opioid ligands. *J. Neurosci. Meth.* 154: 60-67. [IF 1.659]
 16. HUIBAN M, HUET A, **BARRÉ L**, SOBRIO F, FOUQUET E, PERRIO C. (2006). Methyl transfer reaction from monomethyltin reagent under palladium(0) catalysis : a versatile method for labelling with carbon-11. *Chem. Commun.* 1: 97-99. [IF 3.902]
 17. MARTIN C, SANDRINELLI F, PERRIO C, PERRIO S, LASNE M-C. (2006). Oxidation of aromatic lithium thiolates into sulfinate salts. An attractive entry to aryl sulfones labelled with carbon-11. *J. Org. Chem.* 71: 210-214. [IF 3.28]
 18. OUESLATI F, PERRIO C, DUPAS G, **BARRÉ L**. (2007). Diastereoselective conjugate addition of organocuprates to 3,4-dimethyl-5,6-dihydro-1(*1H*)-pyridones. A concise synthesis of trans-3,4-dimethyl-4-phenylpiperidines. *Org. Lett.* 9: 153-156. [IF 3.67]
 19. BOURDIER T, POISNEL G, DHILLY M, DELAMARE J, HENRY J, DEBRUYNE D, **BARRÉ L**. (2007). Synthesis and biological evaluation of N-substituted quinolinimides, as potential ligands for in vivo imaging studies of δ -opioid receptors. *Bioconjugate Chem.* 18: 538-548. [IF 3.044]
 20. BENNACEF I, PERRIO C, LASNE M-C, **BARRÉ L**. (2007). Functionalization through lithiation of (*S*)-N(1-phenylpropyl)-2-phenylquinoline-4-carboxamide. Application to the labelling with carbon-11 of NK-3 receptor antagonist SB 222200. *J. Org. Chem.* 72: 2161-2165. [IF 3.28]

Site de Lille

EA2683 MENRT Diagnostic et Physiopathologie de la maladie de Parkinson

Directeur : Pr. Alain Destée

Institut de Recherche sur le Cancer de Lille,

Place de Verdun, 59045 Lille Cedex

Tel : 03 20 16 92 22

Fax : 03 20 16 92 29

Contact : Dr Marie-Christine Chartier-Harlin, Dr Christel Vanbesien

Email : marie-christine.chartier-harlin@lille.inserm.fr, christel.vanbesien@lille.inserm.fr,

Publications

- 1: **Vanbesien-Mailliot CC**, Wolowczuk I, Mairesse J, Viltart O, Delacre M, Khalife J, **Chartier-Harlin MC**, Maccari S. Prenatal stress has pro-inflammatory consequences on the immune system in adult rats. *Psychoneuroendocrinology*. 2007 Feb;32(2):114-24..
- 2: Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Kruger R, Rocca WA, Schneider NK, Lesnick TG, Lincoln SJ, Hulihan MM, Aasly JO, Ashizawa T, **Chartier-Harlin MC**, Checkoway H, Ferrarese C, Hadjigeorgiou G, Hattori N, Kawakami H, Lambert JC, Lynch T, Mellick GD, Papapetropoulos S, Parsian A, Quattrone A, Riess O, Tan EK, Van Broeckhoven C; Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. *JAMA*. 2006 Aug 9;296(6):661-70.
- 3: Pritchard A, Harris J, Pritchard CW, St Clair D, Lemmon H, Lambert JC, **Chartier-Harlin MC**, Hayes A, Thaker U, Iwatsubo T, Mann DM, Lendon C. Association study and meta-analysis of low-density lipoprotein receptor related protein in Alzheimer's disease. *Neurosci Lett*. 2005 Jul 15;382(3):221-6.
- 4: **Chartier-Harlin MC**, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. *Lancet*. 2004 Sep 25-Oct 1;364(9440):1167-9.
- 5: Levecque C, Destee A, Mouroux V, Amouyel P, **Chartier-Harlin MC**. Assessment of Nurr1 nucleotide variations in familial Parkinson's disease. *Neurosci Lett*. 2004 Aug 12;366(2):135-8.
- 6: Maraganore DM, Lesnick TG, Elbaz A, **Chartier-Harlin MC**, Gasser T, Kruger R, Hattori N, Mellick GD, Quattrone A, Satoh J, Toda T, Wang J, Ioannidis JP, de Andrade M, Rocca WA; UCHL1 Global Genetics Consortium. UCHL1 is a Parkinson's disease susceptibility gene. *Ann Neurol*. 2004 Apr;55(4):512-21.

- 7: Elbaz A, Levecque C, Clavel J, Vidal JS, Richard F, Amouyel P, Alperovitch A, **Chartier-Harlin MC**, Tzourio C. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. *Ann Neurol*. 2004 Mar;55(3):430-4.
- 8: Levecque C, Elbaz A, Clavel J, Vidal JS, Amouyel P, Alperovitch A, Tzourio C, **Chartier-Harlin MC**. Association of polymorphisms in the Tau and Saitohin genes with Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2004 Mar;75(3):478-80.
- 9: Lambert JC, Mann D, Harris J, Araria-Goumidi L, **Chartier-Harlin MC**, Cottel D, Iwatsubo T, Amouyel P, Lendon C. Association study of Notch 4 polymorphisms with Alzheimer's disease. *J Neurol Neurosurg Psychiatry*. 2004 Mar;75(3):377-81.
- 10: Elbaz A, Levecque C, Clavel J, Vidal JS, Richard F, Correze JR, Delemotte B, Amouyel P, Alperovitch A, **Chartier-Harlin MC**, Tzourio C. S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: evidence for an age-dependent relationship. *Mov Disord*. 2003 Feb;18(2):130-7.
- 11: Levecque C, Elbaz A, Clavel J, Richard F, Vidal JS, Amouyel P, Tzourio C, Alperovitch A, **Chartier-Harlin MC**. Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. *Hum Mol Genet*. 2003 Jan 1;12(1):79-86.
- 12: Araria-Goumidi L, Lambert JC, Cottel D, Amouyel P, **Chartier-Harlin MC**. No association of the HLA-A2 allele with Alzheimer's disease. *Neurosci Lett*. 2002 Dec 25;335(2):75-8.
- 13: Araria-Goumidi L, Huguet JB, Lambert JC, Frigard B, Cottel D, Amouyel P, **Chartier-Harlin MC**. No association of the -48CT polymorphism of the presenilin 1 gene with Alzheimer disease in a late-onset sporadic population. *J Neural Transm*. 2002 Jul;109(7-8):1023-7.
- 14: Lambert JC, Araria-Goumidi L, Myllykangas L, Ellis C, Wang JC, Bullido MJ, Harris JM, Artiga MJ, Hernandez D, Kwon JM, Frigard B, Petersen RC, Cumming AM, Pasquier F, Sastre I, Tienari PJ, Frank A, Sulkava R, Morris JC, St Clair D, Mann DM, Wavrant-DeVrieze F, Ezquerra-Trabalon M, Amouyel P, Hardy J, Haltia M, Valdivieso F, Goate AM, Perez-Tur J, Lendon CL, **Chartier-Harlin MC**. Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. *Neurology*. 2002 Jul 9;59(1):59-66.
- 15: Araria-Goumidi L, Lambert JC, Mann DM, Lendon C, Frigard B, Iwatsubo T, Cottel D, Amouyel P, **Chartier-Harlin MC**. Association study of three polymorphisms of TGF-beta1 gene with Alzheimer's disease. *J Neurol Neurosurg Psychiatry*. 2002 Jul;73(1):62-4.
- 16: Green EK, Harris JM, Lemmon H, Lambert JC, **Chartier-Harlin MC**, St Clair D, Mann DM, Iwatsubo T, Lendon CL. Are interleukin-1 gene polymorphisms risk factors or disease modifiers in AD? *Neurology*. 2002 May 28;58(10):1566-8.

- 17: Lambert JC, Mann D, Goumidi L, Harris J, Amouyel P, Iwatsubo T, Lendon C, **Chartier-Harlin MC**. Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease. *Lancet*. 2001 Feb 24;357(9256):608-9.
- 18: Farrer M, Destee A, Levecque C, Singleton A, Engelender S, Becquet E, Mouroux V, Richard F, Defebvre L, Crook R, Hernandez D, Ross CA, Hardy J, Amouyel P, **Chartier-Harlin MC**. Genetic analysis of synphilin-1 in familial Parkinson's disease. *Neurobiol Dis*. 2001 Apr;8(2):317-23.
- 19: Berr C, Lambert JC, Sazdovitch V, Amouyel P, **Chartier-Harlin MC**, Mohr M, Heldt N, Kriesmann M, Hauw JJ. Neuropathological epidemiology of cerebral aging: a study of two genetic polymorphisms. *Neurobiol Aging*. 2001 Mar-Apr;22(2):227-35.
- 20: Mailliot C, Bussiere T, Hamdane M, Sergeant N, Caillet ML, Delacourte A, Buee L. Pathological tau phenotypes. The weight of mutations, polymorphisms, and differential neuronal vulnerabilities. *Ann N Y Acad Sci*. 2000;920:107-14.

U837 Inserm Centre Jean-Pierre Aubert

Directeur : Pierre Formstecher

Equipe « Développement et plasticité du cerveau postnatal »

Responsable d'équipe : Vincent Prévot

Bâtiment Biserte, Place de Verdun,

59045 Lille cedex.

Tel : 03-20-62-20-64

Fax : 03-20-53-85-62

Contact : Dr Vincent Prévot, Dr Carole Ramirez

Email : vincent.prevot@lille.inserm.fr, caroleramirez@free.fr

Publications

1. d'Anglemont de Tassigny X, Campagne C, Dehouck B, Leroy D, Holstein GR, Beauvillain J-C, Buée-Scherrer V, **Prevot V**. Coupling of nNOS to NMDA receptors via PSD-95 depends on estrogen and contributes to the central control of adult female reproduction. *J Neurosci*, in press
2. Sharif A, Legendre P, **Prevot V**, Allet C, Romao L, Studler JM, Chneiweiss H, Junier MP. Transforming growth factor alpha promotes sequential conversion of mature astrocytes into neural progenitors and stem cells. *Oncogene*, 26(19):2695-706, 2007
3. Bouret SG, Simerly RB. Developmental programming of hypothalamic feeding circuits. *Clin Genet*, 70(4):295-301, 2006.

4. Sharif A, **Prevot V**, Renault-Mihara F, Allet C, Studler J-M, Canton B, Chneiweiss H, Junier M-P. Transforming Growth Factor alpha (TGFalpha) acts as a gliatrophin for mouse and human astrocytes. *Oncogene*, 25(29):4076-4085,2006.
5. Gohlke BC, Huber A, Bartmann P, Fimmers R, Hecher K, Bouret SG, Roth CL. Cord blood leptin and IGF-I in relation to birth weight differences and head circumference in monozygotic twins. *J Pediatr Endocrinol Metab*, 19:3-9, 2006
6. **Prevot V**, Lomniczi A, Corfas G, Ojeda SR. erbB-1 and erbB-4 receptors act in concert to facilitate female sexual development and mature reproductive function. *Endocrinology*, 146:1465-1472, 2005.
7. Bouret SG, Draper S, Simerly RB. Trophic action of leptin on hypothalamic neurons that regulate feeding. *Science*, 304:108-110, 2004.
8. De Seranno S, Estrella C, Loyens A, Cornea A, Ojeda S, Beauvillain JC, **Prevot V**. Vascular endothelial cells promote acute plasticity in ependymogial cells of the neuroendocrine brain *J Neurosci*, 24:10353-10363,2004.
9. Bouret SG, Draper S, Simerly RB. Formation of projection pathways from the arcuate nucleus of the hypothalamus to hypothalamic regions implicated in the neural control of feeding behavior in mice. *J Neurosci*, 24:2797-2805, 2004.
10. Bouret S, De Seranno S, Beauvillain JC, **Prevot V**. Transforming growth factor beta1 may directly influence gonadotropin-releasing hormone gene expression in the rat hypothalamus. *Endocrinology*, 145:1794-1801, 2004.
11. **Prevot V**, De Seranno S, Estrella C. Glial-neuronal-endothelial interactions and the neuroendocrine control of GnRH secretion. In: *Nonneuronal cells of the Nervous System: Function and Dysfunction* (Hertz L., Ed), Amsterdam: Elsevier, pp 199-214, 2004.
12. **Prevot V**, Cornea A, Mungenast A, Smiley G, Ojeda SR. Activation of erbB-1 signaling in tanocytes of the median eminence stimulates transforming growth factor 1 release via prostaglandin E2 Production and induces cell plasticity. *J Neurosci*, 23:10622-10632, 2003.
13. **Prevot V**, Rio C, Cho G, Heger S, Neville CM, Rosenthal NA, Ojeda SR, Corfas G. Normal female sexual development requires erbB receptor signaling in hypothalamic astrocytes. *J Neurosci*, 23:230-239, 2003
14. Dziedzic B, **Prevot V**, Lomniczi A, Jung H, Cornea A, Ojeda SR. Neuron-to-glia signaling mediated by excitatory amino acid receptors regulates erbB receptor function in astroglial cell of the neuroendocrine brain. *J Neurosci*, 23:915-926, 2003.
15. Ojeda SR, Prevot V, Heger S, Lomniczi A, Dziedzic B, Mungenast A. Glia-to-neuron signaling and the neuroendocrine control of female puberty. *Ann Med*, 35:244-255, 2003.
16. Ojeda SR, **Prevot V**, Heger S, Lomniczi A, Dziedzic B, Mungenast A. The Neurobiology of Female Puberty. *Horm Res*, 60 (suppl 3):15:20, 2003.

17. Ojeda SR, **Prevot V**, Heger S, Dziedzic B. GnRH and Puberty. Encyclopedia of Hormones, HL Henry, AW Norman (Eds), Academic press, San Diego, CA, pp 165-171, 2003.
 18. Poulain P, Decroq N, Mitchell V. Direct inhibitory action of galanin on hypothalamic arcuate nucleus neurones expressing galanin receptor Gal-r1 mRNA. Neuroendocrinology, 78:105-117, 2003.
 19. **Prevot V** Glial-neuronal-endothelial interactions are involved in the control of GnRH secretion. J Neuroendocrinology, 14:247-255, 2002.
 20. **Prevot V**, Croix D, Bouret S, Dutoit S, Tramu G, Stefano GB, Beauvillain JC. Definitive evidence for the existence of morphological plasticity in the external zone of the median eminence during the rat estrous cycle: implication of neuro-glio-endothelial interactions in gonadotropin-releasing hormone release. Neuroscience, 94(3):809-819,1999.
1. **Ramirez C**, Delrieu O, Mineo JF, Paradot G, Allaoui M, Dubois F, Blond S. Intracranial dissemination of primary spinal cord anaplastic oligodendroglioma. Eur J Neurol. 2007 May;14(5):578-80.
 2. **Ramirez CB**, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months .J Surg Res. 2007 Apr;138(2):198-204. Epub 2007 Feb 8.
 3. Mineo JF, Bordron A, Baroncini M, **Ramirez C**, Maurage CA, Blond S, Dam-Hieu P. Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir (Wien). 2007 Mar;149(3):245-53. Epub 2007 Feb 2.
 4. **Ramirez CB**, Marino IR. The role of basiliximab induction therapy in organ transplantation. Expert Opin Biol Ther. 2007 Jan;7(1):137-48. Review.
 5. **Ramirez CB**, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months. Transplant Proc. 2006 Dec;38(10):3633-5. Erratum in: Transplant Proc. 2007 Apr;39(3):779.

Equipe de Psycho-oncologie du Centre Oscar Lambret

Responsable : Michel Reich

Centre Oscar Lambret

3 rue Frédéric Combemale

59020 Lille cedex, BP307-France

Tél : 03 20 29 55 86

Fax : 03 20 29 55 74

Contact : Dr Reich Michel

Email : M-Reich@o-lambret.fr

Publications

1. **Reich M**, Ait-Kaci F, Sedda AL. La détresse psychologique sous toutes ses formes. In : Dolbeault S, Dauchy S, Consoli SM. La psycho-oncologie Ed. John Libbey Eurotext, Paris, 2007, 58-76.
2. Lefetz C, **Reich M**. La crise suicidaire en cancérologie : évaluation et prise en charge. Bull Cancer 2006 ;93(7) : 709-13
3. **Reich M**, Ait-Kaci F, Sedda AL. Psycho-oncologie et pluridisciplinarité : l'exemple d'une collaboration entre psychologue et psychiatre au sein du Centre de lutte contre le cancer de Lille. Eurocancer 2006, John Libbey Eurotext, Paris 2006, pp275-276
4. **Ait-Kaci F**, Reich M, **Ulaszewski AL**. **Croyances et médecines complémentaires et alternatives en cancérologie : le point de vue du psycho-oncologue . Rev Francoph Psycho-Oncologie 2006 : 5(3) : 165-169**
5. **Reich M**, Ait-Kaci F, Sedda AL, Neu JC. Les proches : les exclus des soins de support ? Rev Francoph Psycho-Oncologie 2006 : 5(4) :221-226
- Rozniatowski O., **Reich M.**, Malet Y., Penel P., Fournier C., Lefebvre JL.. Psychosocial factors involved in delayed consultation by patients with head and neck cancer. Head and Neck Cancer 2005 ;27(4) : 274-80
6. **Reich M**. Cancers, croyances et spiritualités. Editorial. Rev Francoph Psycho-Oncologie 2005 ; 4 :235-236
- Elek T, **Reich M**. Place des antidépresseurs sérotoninergiques dans la prise en charge des bouffées de chaleur en cancérologie. Revue de Médecine Interne 2004 ;25 :217-224
7. **Reich M**. Répercussions psychologiques de l'alopecie. Bulletin Infirmier du Cancer 2004 ; 4(1) :7-11
- Reich M**, Dolbeault S, Seigneur E, Dauchy S, Marx E. Compte rendu du congrès international de Psycho-Oncologie de 2004, Copenhague. Revue Francophone de Psycho-Oncologie 2004 ; 3(3) : 162-167
8. **Reich M**. L'information diagnostique et pronostique à l'épreuve des avancées thérapeutiques en cancérologie : réflexions éthiques. Revue Francophone de Psycho-Oncologie 2004 ; 3(4) : 188-196
9. **Reich M**, Mekaoui L. La conspiration du silence en cancérologie : une situation à ne pas négliger. Bulletin du cancer 2003 ; 90 (2) : 181-4.
10. **Reich MG**, Gagnon P, Gaudreau PO, Breitbart W.
Revue des instruments d'évaluation de la confusion mentale ("delirium") en cancérologie. Revue Francophone de Psycho-Oncologie 2003;1-2(2):30-37
11. Schiaratura L, Christophe V, Adenis C, Peyrat JP, **Reich M**, Vennin P.
Première consultation d'oncogénétique de prédisposition au cancer du sein et de l'ovaire : transmission de l'information et impact émotionnel. Revue Francophone de Psycho-Oncologie 2003,1-2 (2):43-48

- 12. Reich M**, Lassaunière JM. Prise en charge de la confusion mentale (« delirium ») en soins palliatifs : l'exemple du cancer. *Médecine Palliative* 2003;2:55-71
13. Herbaut A, **Reich M**, Horner-Vallet D. Evaluation de la détresse psychologique en soins palliatifs. A propos de 50 observations. *INFOKara* 2003 ; 18(1) : 5-10
14. Legrand E, **Reich M**. Dimension éducative dans l'annonce diagnostique du cancer. *Revue Francophone de Psycho-Oncologie* 2003 ;2(4) :178-181
- 15. Reich M**, Chauvenet L. Rechute du cancer de l'ovaire : annonce de la rechute : impact psychologique. *Dialogues interdisciplinaires en oncologie. Laboratoires Schering-Plough*, juillet 2002 : 2-9.
16. Penel N, Ulaszewski AL, **Reich M**. La vérité au malade : le témoignage d'Arthur et Isabelle Rimbaud. *La Presse Médicale* 2001, 30(13) : 636-638.
- 17. Reich M**, Deschamps C, Ulaszewski AL, Horner-Vallet D. L'annonce d'un diagnostic de cancer : paradoxes et quiproquos. *Revue de médecine interne* 2001, 22 :560-566

Service de Psychiatrie Adulte du CHU de Lille

Chef de Service : Pr Michel Goudemand

Equipe de Psychiatrie Addictologie et Psycho-Oncologie de liaison

Responsable : Olivier Cottencin

Hôpital FONTAN

Rue Verhaeghe

59037 LILLE

Tel: 03 20 44 47 04

Fax: 03 3 20 44 62 65

Contact : Dr Olivier Cottencin

Email : OCOTTENCIN@CHRU-LILLE.FR

Publications

1. **Cottencin O**, Warembourg F, de Chouly de Lenclave MB, Lucas B, Vaiva G, Goudemand M, Thomas P.

Catatonia and Consultation-Liaison Psychiatry. Study on 12 cases. *Prog Neuropsychopharmacol Biol Psychiatry*. Neuro (sous presse)

2. Tir M, Devos D, Blond S, Touzet G, Reyns N, Duhamel A, Waucquier N, **Cottencin O**, Dujardin K, Debailleul AM, Cassim F, Destee A, Defebvre L, Krystkowiak P. Exhaustive, one-year follow-up of subthalamic nucleus deep brain stimulation in a large, single-center cohort of parkinsonian patients. *Neurosurgery*. 2007 Mar 15; [Epub ahead of print]

3. Thomas P, **Cottencin O**, Rascle C, Vaiva G, Goudemand M. Catatonia in French Psychiatry: Implications of the Zolpidem Challenge Test. *Psychiatric Annals* 2007; 37(1): 45-54
4. Karila L, Ferreri M, Coscas S, **Cottencin O**, Benyamina A, Reynaud M. Self-mutilation induced by cocaine abuse: the pleasure of bleeding. *Presse Med.* 2007 Feb; 36(2 Pt 1):235-7. Epub 2006 Dec 20.
5. Devos D, Krystkowiak P, Clement F, Dujardin K, **Cottencin O**, Waucquier N, Ajebbar K, Thielemans B, Kroumova M, Destée A, Bordet R, Defebvre L. Improvement of gait by chronic high doses of methylphenidate in advanced parkinsonian patients. *J Neurol Neurosurg Psychiatry.* 2006 Nov 10; [Epub ahead of print]
6. Pillon B, Ardouin C, Dujardin K, Vittini P, Pelissolo A, **Cottencin O**, Vercueil L, Houeto JL, Krystkowiak P, Agid Y, Destee A, Pollak P, Vidailhet M; French SPIDY Study Group. Preservation of cognitive function in dystonia treated by pallidal stimulation. *Neurology.* 2006 May 23; 66(10):1556-8.
7. **Cottencin O**, Vaiva G, Huron C, Devos P, Ducrocq F, Jouvent R, Goudemand M, Thomas P. Forgetting in PTSD: a comparative study versus normal controls. *J Psychiatr Res.* 2006; 40(1):70-80. Directed.
8. Vaiva G, Thomas P, Ducrocq F, Fontaine M, Boss V, Devos P, Rascle C, **Cottencin O**, Brunet A, Laffargue P, Goudemand M. Low posttrauma GABA plasma levels as a predictive factor in the development of acute posttraumatic stress disorder. *Biol Psychiatry.* 2004 Feb 1;55(3):250-4
9. Vaiva G, Jehel L, **Cottencin O**, Ducrocq F, Duchet C, Omnes C, Genest Ph, Rouillon F, Roelandt JL. Prévalence des troubles psychotraumatiques en France métropolitaine (IF = 0.443) *L'Encéphale* 2007 (accepté sous presse)
10. Krystkowiak P, Devos D, Dujardin K, Delmaire C, Bardinet E, Delval A, Delliaux M, **Cottencin O**, Simonin C, Yelnik J, Blond S, Defebvre L, Destée A; Le Réseau Huntington de langue française. Impact cognitif et moteur de la stimulation du pallidum externe dans la maladie de Huntington : données préliminaires (IF = 0.443). *Rev Neurol (Paris).* 2007 Jan;163(1 Suppl):34-5.
11. **Cottencin O**, Versaevel C, Goudemand M. Pour une vision systémique de la Psychiatrie de Liaison *L'Encéphale* 2006;32(3 Pt 1):305-14
12. Bellone M, **Cottencin O**, Rigot JM, Goudemand M. Étude des troubles psychiatriques et des modalités défensives évaluées par le "Defense Style Questionnaire" (DSQ) dans une population d'hommes stériles consultants en Andrologie. *L'Encéphale.* 2005 ; 31(4):414-25.
13. Thomas P, Vaiva G, Maron M, **Cottencin O**, Goudemand M. Les traitements adjuvants au cours de l'épisode maniaque. *L'Encéphale*, 2004 ; 30 (1) : 80-9.

Site de Rouen

Unité 413 Inserm Laboratoire de Neuroendocrinologie Cellulaire et Moléculaire

Directeur : Hubert Vaudry
Place Emile Blondel,
Université de Rouen,
76821 Mont-Saint-Aignan
Tel : 02-35-14-66-30
Fax : 02-35-14-69-46

Contact : Dr Hélène Castel, Dr Pierrick Gandolfo, Dr David Vaudry

Email : helene.castel@univ-rouen.fr, pierrick.gandolfo@univ-rouen.fr, david.vaudry@univ-rouen.fr,

Publications

1. Do Rego J.L., Tremblay Y., Luu-The V., Repetto E., **Castel H.**, Vallarino M., [Belanger](#), Pelletier G., Vaudry H. Immunohistochemical localization and biological activity of the steroidogenic enzyme cytochrome P450 17alpha-hydroxylase/C17, 20-lyase (P450C17) in the frog brain and pituitary. *J. Neurochem.* 2007, 100:251-268.
2. **Castel H.**, Chatenet D., Diallo M., Leprince J., Desrues L., Schouft M.T., Fontaine M., Dubessy C., Lihmann I., Scalbert E., Malagon M., Vaudry H., Tonon M.C. and **Gandolfo P.** Biochemical and functional characterization of high affinity urotensin II receptors in rat cortical astrocytes. Evidence for two distinct binding sites. *J. Neurochem.* 2006, 99:582-595.
3. **Castel H.**, **Vaudry D.**, Mei Y.A., Lefebvre T., Basille M., Desrues L., Fournier A., Vaudry H., Tonon M.C. and Gonzalez B.J. The delayed rectifier channel current I_K plays a key role in the control of programmed cell death by PACAP and ethanol in cerebellar granule neurons. *Ann. N.Y. Acad. Sci.* 2006, 1070:173-179.
4. Ravni A., Eiden L.E., Vaudry H., Gonzalez B.J. and **Vaudry D.** Cycloheximide treatment to identify components of the transitional transcriptome in PACAP-induced PC12 cell differentiation. *J. Neurochem.* 2006, 98:1229-1241 .
5. Ravni A., Bourgault S., Lebon A., Chan P., Galas L., Fournier A., Vaudry H., Gonzalez B., Eiden L.E. and **Vaudry D.** The neurotrophic effects of PACAP in PC12 cells: control by multiple transduction pathways. *J. Neurochem.* 2006, 98:321-9.
6. Masmoudi-Kouki O., **Gandolfo P.**, Leprince J., **Vaudry D.**, Pelletier G., Fournier A., Vaudry H. and Tonon M.C. PACAP stimulates biosynthesis and release of endozepines from rat astrocytes. *Ann. N Y Acad. Sci.* 2006, 1070:411-416.
7. Falluel-Morel A., **Vaudry D.**, Aubert N., Galas L., Bénard M., Basille M., Fontaine M., Fournier A., Vaudry H. and Gonzalez B.J. Pituitary adenylate cyclase-activating polypeptide prevents the effects of ceramides on migration, neurite outgrowth, and cytoskeleton remodeling. *Proc. Natl. Acad. Sci. USA* 2005, 102:2637-2642.

8. **Castel H.**, Desrues L., Malagon M.M., Vaudry H. and Tonon M.C. The regulation of α -MSH release by GABA is mediated by a chloride-dependent $[Ca^{2+}]_i$ increase in frog melanotrope cells. *Peptides* 2005, 26:1936-1943.
9. Tokay T., Masmoudi O., **Gandolfo P.**, Leprince J., Pelletier G., Vaudry H. and Tonon M.C. Beta-amyloid peptides stimulate endozepine biosynthesis in cultured rat astrocytes. *J. Neurochem.* 2005, 94:607-616.
10. Masmoudi O., **Gandolfo P.**, Tokay T., Leprince J., Ravni A., Vaudry H. and Tonon, M.C. Somatostatin down-regulates the expression and release of endozepines from cultured rat astrocytes via distinct receptor subtypes. *J. Neurochem.* 2005, 94:561-571.
11. Mei Y.A., **Vaudry D.**, Basille M., **Castel H.**, Fournier A., Vaudry H. and Gonzalez, B.J. PACAP inhibits delayed rectifier potassium current via a cAMP/PKA transduction pathway. Evidence for the involvement of I_K in the anti-apoptotic action of PACAP. *Eur. J. Neurosci.* 2004, 19:1446-1458.
12. **Vaudry D.**, Falluel-Morel A., Basille M., Pamantung T.F., Fontaine M., Fournier A., Vaudry H. and Gonzalez B.J. Pituitary adenylate cyclase-activating polypeptide prevents C2-ceramide-induced apoptosis of cerebellar granule cells. *J. Neurosci. Res.* 2003, 72:303-316.
13. Masmoudi O., **Gandolfo P.**, Leprince J., **Vaudry D.**, Fournier A., Patte-Mensah C., Vaudry H. and Tonon M.C. Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates endozepine release from cultured rat astrocytes via a PKA-dependent mechanism. *FASEB J.* 2003, 17:17-27.
14. **Vaudry D.**, Rousselle C., Basille M., Falluel-Morel A., Pamantung T.F., Fontaine M., Fournier A., Vaudry H. and Gonzalez B.J. Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death. *Proc. Natl. Acad. Sci. USA* 2002, 99:6398-6403.
15. **Vaudry D.**, Stork P.J. Lazarovici P. and Eiden L.E. Signaling pathways for PC12 cell differentiation: making the right connections. *Science* 2002, 296:1648-1649.
16. **Castel H.** and Vaudry H.: Nitric oxide directly activates GABA_A receptor function through a cGMP/protein kinase-independent pathway in frog pituitary melanotrophs. *J. Neuroendocrinol.* 2001, 13:695-705.
17. **Gandolfo P.**, Louiset E., Patte C., Leprince J., Masmoudi O., Malagon M., Gracia-Navarro F., Vaudry H. and Tonon M.C. The triakontratetranuropeptide TTN increases $[Ca^{2+}]_i$ in rat astrocytes through activation of peripheral-type benzodiazepine receptors. *Glia* 2001, 35:90-100.
18. **Castel H.**, Jégou S., Tonon M.C. and Vaudry H. Regulation of the GABA_A receptor by nitric oxide in frog pituitary melanotrophs. *Endocrinology* 2002, 141:3451-3460.
19. **Castel H.**, Louiset E., Anouar Y., Le Foll F., Cazin L. and Vaudry H. Regulation of GABA_A receptor by protein tyrosine kinases in frog pituitary melanotrophs. *J. Neuroendocrinol.* 2000, 12:41-52.

- 20. Gandolfo P.,** Patte C., Leprince J., Rego J.L., Mensah-Nyagan A.G., Vaudry H. and Tonon M.C.
The triakontatetrapeptide (TTN) stimulates thymidine incorporation in rat astrocytes through peripheral-type benzodiazepine receptors. *J. Neurochem.* 2000, 75:701-707.

UMR 6522 CNRS Laboratoire Polymères, Biopolymères, Membranes

Directeur : Guy-Alain JUNTER

UFR des Sciences et Techniques

Bd Maurice de Broglie

76821 MONT-SAINT-AGNAN cedex

Tél: +33 2 35 14 63 97

Fax: +33 2 35 14 67 04

Contact : Dr Pascal Cosette

Email : pascal.cosette@univ-rouen.fr

Publications

1. C Duval, **P Cosette**, G Muller, G Molle and E Dé (2003) Amphiphilic biopolymers (Amphibiopols) as new surfactants for membrane proteins solubilisation. *Prot. Sci.* 12, 681-689.
2. M. Bardor, C Loutelier-Bourhis, T Paccalet, **P Cosette**, AC Fitchette, L Vezina, S, Trepanier, M Dargis, R Lemieux, C Lange, L Faye and P Lerouge (2003) Monoclonal antibody produced in transgenic alfalfa plants exhibits a N-glycosylation that is perfect for glyco-engineering into human-compatible structures. *Plant Biotechnology Journal* 1, 451-462.
3. S Vilain, **P Cosette**, I Zimmerlin, JP Dupont, GA Junter and T Jouenne (2004) The biofilm proteome : unicity or versatility? *J Proteome Res.* 3, 132-6.
4. S. Vilain, **P Cosette**, M. Hubert, C Lange, GA Junter et T Jouenne (2004) Proteomic analysis of agar gel-entrapped *Pseudomonas aeruginosa*. *Proteomics*.4, 1996-2004.
5. T Jouenne, S Vilain, **P Cosette** et GA Junter (2004) Proteomics of biofilms bacteria. *Curr. Proteomics* 1, 113-129.
6. S. Vilain, **P Cosette**, M. Hubert, C Lange, GA Junter et T Jouenne (2004) Comparative proteomic analysis of planktonic and immobilized *Pseudomonas aeruginosa* cells: a multivariate statistical approach. *Anal. Biochem.* 329,120-30.
7. D Seyer, **P Cosette**, A. Siroy, E Dé, C Lenz, H Vaudry, L Coquet and T Jouenne (2005) Proteomic comparison of outer membrane protein patterns of sessile and planktonic *Pseudomonas aeruginosa* cells. *Biofilms* 2, 27-36.
8. H Manduzio, **P Cosette**, L Gricourt, T Jouenne, C Lenz, F Leboulenger and B Rocher (2005) Proteome modifications of blue mussel (*Mytilus edulis*) gills as an effect of water pollution. *Proteomics*, 5, 4958-4963.

9. JM Conlon, T Jouenne, **P Cosette**, D Cosquer, H Vaudry, CK Taylor and PW Abdel (2005) Bradykinin-related peptides and tryptophyllins in the skin secretions of the most primitive extant frog, *Ascaphus Truei*. *Gene. Comp. Endoc.*, 143, 193-199.
10. L Coquet, **P Cosette**, E Dé, L. Galas, H Vaudry, P Lerouge, C Rihouey, GA Junter and T Jouenne (2005) Immobilization induces alterations in the outer membrane protein pattern of *Yersinia ruckeri*. *Journal of Proteome Research*, 4, 1988-1998.
11. JM Conlon, B Abraham, A Sonnevend, T Jouenne, **P Cosette**, J Leprince, H Vaudry and CR Bevier (2005) Purification and characterization of antimicrobial peptides from the skin secretions of the carpenter frog *Rana virgatipes*. *Regulatory Peptides.*, 131, 38-45.
12. L Coquet, S Vilain, **P Cosette** et T Jouenne and GA Junter (2006) A proteomic approach of biofilm cell physiology. In *Methods in Biotechnology, Immobilization of enzymes and cells*, 3rd Ed., J.M. Guisan © Humana Press Inc. Totowa, 403-414.
13. N Chartrel, F Bruzzone, J Leprince, H Tollemmer, Y Anouar, J Do-Régo, I Ségalas-Milazzo, L Guilhaudis, **P Cosette**, T Jouenne, G Simonnet, JC Beauvillain, J Costentin, H Vaudry (2006) Structure and functions of the novel hypothalamic RFamide neuropeptides R-RFa and 26RFa in vertebrates. *Peptides* 27, 1110-1120.
14. A LEBON, D SEYER, **P COSETTE**, L COQUET, T JOUENNE, P CHAN, J LEPRINCE, A FOURNIER, H VAUDRY, B GONZALEZ and D VAUDRY (2006) Identification of proteins regulated by PACAP in PC12 cells by 2D gel electrophoresis coupled to mass spectrometry. *Ann. N. Y. Acad. Sci.*, 1070, 380-387.
15. JM CONLON, N AL-GHAFFERI, B ABRAHAM, H JIANSBERG, **P COSETTE**, J LEPRINCE, T JOUENNE and H VAUDRY (2006) Antimicrobial peptides from diverse families isolated from the skin of the Asian frog, *Rana grahami*. *Peptides*, 27-2211-2217.
16. D Lienard, O Tran Dinh1, E van Oort, L Van Overtvelt, C Bonneau, E Wambre, M Bardor, **P Cosette**, A Didier-Laurent, F Dorlhac de Borne, R Delon, R van Ree, P Moingeon, L Faye and V Gomord (2007) Suspension-cultured BY-2 tobacco cells produce and mature immunologically active house dust mite allergens. *Plant Biotech J.* 5, 93-108.
17. A COLLET, S VILAIN, **P COSETTE**, G-A JUNTER, T JOUENNE, RS PHILLIPS, P DI MARTINO (2007) Protein expression in *Escherichia coli* S17-1 biofilms: impact of indole. *Antonie van Leeuwenhoek* 91, 71-85.
18. A SIROY, **P COSETTE**, D SEYER, C LEMAITRE-GUILLER, D VALLENET, A VAN DORSSELAER, S BOYER-MARITTE, T JOUENNE, E DE (2006) Global comparison of the membrane subproteomes between a MDR *Acinetobacter baumannii* strain and a reference strain. *J Proteome Res.* 5, 3385-3398.
19. L BENARD, P-Y LITZLER, **P COSETTE**, J-F LEMELAND, T JOUENNE and G-A JUNTER. Proteomic analysis of *Staphylococcus aureus* biofilms grown in vitro on mechanical heart leaflets. *J Biomedical Materials Research: Part A*. Sous presse.

FRE 2735 CNRS Unité de Neuropsychopharmacologie Expérimentale

Directeur : Jean Costentin

Faculté de Médecine et Pharmacie

Université de Rouen

22 boulevard Gambetta

76183 Rouen Cedex

Tel : 02-35-14-86-02

Fax : 02-35-14-86-02

Contact : Dr Jean-Claude Dorego

Email : dorego.jean-claude@chu-rouen.fr

Publications

1. **Do REGO Jean-Claude**, Suaudeau Charles, Chapouthier Georges and Costentin Jean. Mouse lines differing in sensitivity to μ -CCM differ in tasks used for testing antidepressants. *Pharmacol. Biochem. Behav.* 72, 411-416 (2002). IF: 2.31
2. Chartrel N., Dujardin C., Anouar Y., Leprince J., Decker A., Clerens S., **do REGO Jean-Claude**, Vandesande F., Llorens-Cortes C., Costentin J., Beauvillain J.-C. and Vaudry H. Identification of 26RFa, a hypothalamic neuropeptide of the RFamide peptide family with orexigenic activity. *Proc. Nat. Acad. Sci. USA* 100, 15247-15252 (2003). IF: 10.27
3. Fichna J., **do REGO Jean-Claude**, Costentin J., Chung N. N., Schiller P. W., Kosson P. and Janecka A. Opioid receptor binding and *in vivo* antinociceptive activity of position 3-substituted morphiceptin analogs. *Biochem. Biophys. Res. Comm.* 320, 531-536 (2004). IF: 3.00
4. Fichna J., **do REGO Jean-Claude**, Kosson P., Costentin J. and Janecka A. Characterization of antinociceptive activity of novel endomorphin-2 and morphiceptin analogs modified in third position. *Biochem. Pharmacol.* 69, 179-185 (2005). IF: 3.62
5. Fichna J., **do REGO Jean-Claude**, Morowski M., Byszewska E., Costentin J. and Janecka A. Binding of endomorphin-2 to μ -opioid receptors in experimental mouse mammary adenocarcinoma. *J. Pept. Res.* 65, 459-464 (2005). IF: 1.74
6. Kruszynski R., Fichna J., **do REGO Jean-Claude**, Chung N.N., Schiller P.W., Kosson P., Costentin J. and Janecka A. Novel endomorphin-2 analogs with μ -opioid receptor antagonist activity. *J. Pept. Res.* 66, 125-131 (2005). IF: 1.74
7. Suaudeau Charles, **do REGO Jean-Claude** and Costentin Jean. Modifications in avoidance reactions of mice, on a second exposure to the hot plate, resist to various amnesia-inducing treatments. *Cognitive Brain Research* 25, 339-347 (2005). IF: 2.87

8. Viana Alice, **do REGO Jean-Claude**, Von Poser G.L., Ferraz A.F., Heckler A.P., Costentin Jean and Rates Stela Maris. The antidepressant-like effect of *Hypericum caprifoliatum* Cham & Schlecht (Guttiferae) on forced swimming test results from an inhibition of neuronal monoamine uptake. *Neuropharmacology* 49, 1042-1052 (2005). IF : 3.81
9. **do REGO Jean-Claude**, Chatenet D., Orta M.-H., Naudin B., Le Cudennec C., Leprince J., Scalbert E., Vaudry H. and Costentin J. Behavioral effects of urotensin-II centrally administered in mice. *Psychopharmacology* 183, 103-117 (2005). IF: 3.99
10. Kruszynski R., Fichna J., **do REGO Jean-Claude**, Janecki T., Kosson P., Costentin J. and Janecka A. Synthesis and biological activity of N-methylated analogs of endomorphin-2. *Bioorg. Med. Chem.* 13, 671-6717 (2005). IF: 2.29
11. Janecka A., Fichna J., Kruszynski R., Sasaki Y., Ambo A., Costentin J. and **do REGO Jean-Claude**. Synthesis and antinociceptive activity of cyclic endomorphin-2 and morphiceptin analogs. *Biochem. Pharmacol.* 71, 188-195 (2005). IF: 3.62
12. **do REGO Jean-Claude**, Viana F. Alice, Le Maitre Erwan, Deniel Audrey, Leroux-Nicolet Isabelle, Costentin Jean. Comparisons between anxiety tests for selection of anxious and non anxious mice. *Behavioral Brain Research* 169, 282-288 (2006). IF: 2.87
13. Chartrel N., Bruzzone F., Leprince J., Tollemer H., Anouar Y., **do REGO Jean-Claude**, Segalas-Milazzo I., Guilhaudis L., Cosette P., Jouenne T., Simonnet G., Vallarino M., Beauvillain J.-C., Costentin J. and Vaudry H. Structure and functions of the novel hypothalamic RFamide neuropeptides R-RFa and 26RFa in vertebrates. *Peptides* 27, 1110-1120 (2006). IF: 2.44
14. Fichna J., **do REGO Jean-Claude**, Kosson P., Costentin J. and Janecka A. [³⁵S]GTPγS binding stimulated by endomorphin-2 and morphiceptin analogs. *Biochem. Biophys. Res. Comm.* 345, 162-168 (2006). IF: 3.00
15. Fichna Jakub, Janecka Anna, Bailly Laetitia, Marsais Francis, Costentin Jean and **do REGO Jean-Claude**. *In vitro* characterization of novel peptide inhibitors of endomorphin-degrading enzymes in the rat brain. *Chem. Biol. Drug Des.* 68, 173-175 (2006). IF: 1.74
16. **do REGO Jean-Claude**, Leprince Jérôme, Chartrel Nicolas, Vaudry Hubert and Costentin Jean. Behavioral effects of 26RFamide and related peptides. *Peptides* 27, 2715-2721 (2006). IF: 2.44
17. Viana Alice, **do REGO Jean-Claude**, Munari Leonardo, Dourmap Nathalie, Heckler Ana Paula, Von Poser Gilsane L., Costentin Jean, Rates M.K. Stela. *Hypericum caprifoliatum* (Guttiferae) Cham. & Schldl. : a species native to south Brazil with antidepressant like activity. *Fund. Clin. Pharmacol.* 20, 507-514 (2006). IF: 1.72
18. Fichna Jakub, Janecka Anna, Piestrzeniewicz Mariola, Costentin Jean and **do REGO Jean-Claude**. Antidepressant-like effect of endomorphin-1 and endomorphin-2 in mice. *Neuropsychopharmacology* 32, 813-821 (2007). IF: 5.37

19. Fichna J., **do REGO Jean-Claude**, Chung N.N., Lemieux C., Schiller P.W., Poels J., Broek J.V., Costentin J. and Janecka A. Synthesis and characterisation of potent and selective μ -opioid receptor antagonists, [Dmt¹,D-2-Nal⁴]endomorphin-1 (antanal-1) and [Dmt¹, D-2-Nal⁴]endomorphin-2 (antanal-2). *J. Med. Chem.* 50, 512-520 (2007). *IF: 4.93*
20. Fichna Jakub, Janecka Anna, Costentin Jean and **do REGO Jean-Claude**. The endomorphin system and its evolving neurophysiological role. *Pharmacol. Rev.* 59, 88-123 (2007). *IF: 27.07*